Health Trials

Follicular T-Cell Lymphoma

3

Review clinical trials related to Follicular T-Cell Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Registry for People With T-cell Lymphoma

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Participants needed: 1,000
Trial details
Biological sex: AllType: ObservationalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: May 20, 2026Locations: 26Duration: 10 Years
Eligibility criteria

Written informed consent [+30]

Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymp... [+1]

Read more
Status: Recruiting

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).

Participants needed: 150
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Corvus Pharmaceuticals, Inc.Updated: Apr 8, 2026Locations: 34
Eligibility criteria

Adult participants ≥18 years of age on the day of signing the informed consent f... [+19]

Participants who have T-cell lymphoma with active central nervous system involve... [+17]

Read more
Status: Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

Participants needed: 46
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SciTech Development, Inc.Updated: Sep 22, 2025Locations: 10
Eligibility criteria

Cutaneous T-cell lymphoma (CTCL): mycosis fungoides (MF), Sézary Syndrome (SS),... [+21]

Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for n... [+11]

Read more